Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers

Yakun Wang,1,‡ Tianshu Liu,2,§ Gongyan Chen,3,¶ Jifang Gong,4 Yuxian Bai,5 Tao Zhang,6 Nong Xu,7 Li Liu,6 Jianming Xu,8 Jianxing He,9,10 Yunpeng Liu,11 Li Zhang,12,13,14 Da Jiang,15 Mengzhao Wang,16 Jianhua Chang,17,18 Wei Li,19 Chunmei Bai,20 Jinghong Zhou,21 Jian Wang,21 Yongxin Ren,21 Liya Zhang,21 Weiguo Su,21 Baorui Liu,22,* Lin Shen4,*,‡

1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Early Drug Development Center, Peking University Cancer Hospital & Institute, Beijing, People’s Republic of China
2Department of Medical Oncology, Zhongshan Hospital, and Center of Evidence-Based Medicine, Fudan University, Shanghai, People’s Republic of China
3Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology/Early Drug Development Center, Peking University Cancer Hospital & Institute, Beijing, People’s Republic of China
4Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, People’s Republic of China
5Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
6Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China
7Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, People’s Republic of China
8Department of Thoracic Surgery/Oncology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
9State Key Laboratory and National Clinical Research Center for Respiratory Disease, Guangzhou, People’s Republic of China
10Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, People’s Republic of China
11Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, People’s Republic of China
12State Key Laboratory of Carcinogenesis and Translational Research in South China, Guangzhou, People’s Republic of China
13Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China
14Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China
15Department of Medical Oncology, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
16Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
17Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
18Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, People’s Republic of China
19Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of China
20Department of Medical Oncology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, People’s Republic of China
21Hutchison China MediTech Limited, Shanghai, People’s Republic of China
22The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, People’s Republic of China

*Corresponding author: Shen Lin, MD, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology/Early Drug Development Center, Peking University Cancer Hospital & Institute, Fu-Cheng Road 52, Hai-Dian District, Beijing 100142, People’s Republic of China. Tel: +86 10 88196561; Email: shenlin@bjmu.edu.cn; or, Baorui Liu, MD, The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University. No. 321, Zhongshan Road, Nanjing, 210000, People’s Republic of China. Telephone: +86-25-83105082; email: baorui.liu@nju.edu.cn.

Contributed equally.

Principal Investigator: Lin Shen

Abstract

Background: Savolitinib has shown good tolerability and preliminary efficacy, but efficacy biomarkers require investigation. The main purpose of this study was to confirm in Chinese patients the recommended phase II dose (RP2D) of savolitinib and to explore overall benefit in tumors bearing c-Met aberration.

Methods: This was an open-label, multi-center, 2-part phase I study. A starting dose of 600 mg QD was initiated in the escalation phase, utilizing a 3+3 design with repeated QD and BID dosing. In the dose expansion phase, we enrolled patients with gastric cancer and non-small cell lung cancer (NSCLC) with documented c-met aberration into 5 cohorts to further explore biomarkers. c-Met overexpression and amplification were assessed by immunohistochemistry and FISH, respectively.

Received: 2 July 2021; Accepted: 4 October 2021.

© The Author(s) 2022. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

The data published online to support this summary are the property of the authors. Please contact the authors about reuse rights of the original data.
Results: The safety analysis set included 85 patients. Only one dose-limiting toxicity (grade 3 fatigue) was reported in the 600 mg BID dosing group. The most frequent treatment-related adverse events were nausea (29.4%), vomiting (27.1%), and peripheral edema (21.2%). Notably, in gastric cancer, response was only observed in patients with MET amplification (copy number 9.7-18.4), with an objective response rate of 35.7% and a disease control rate of 64.3%. For patients with NSCLC bearing a MET exon 14 skipping mutation, obvious target lesion shrinkage was observed in 2 of 4 patients, although PR was not achieved.

Conclusion: The RP2D of savolitinib was established as 600 mg QD or 500 mg BID in Chinese patients. The promising response observed in patients with gastric cancer with c-met amplification and NSCLC with MET exon 14 skipping mutation warrants further investigation.

ClinicalTrials.gov Identifier: NCT0198555

Key words: savolitinib; C-met inhibitor; targeted therapy; biomarker.

Lessons Learned
- The recommended dose for savolitinib monotherapy in Chinese patients was determined to be 500 mg BID or 600 mg QD.
- Responses were observed in gastric cancers with MET amplification with gene copy number of 9.7-18.4; signs of antitumor activity were observed in NSCLCs with exon 14 skipping mutation.
- Heterogeneity in response in target and non-target lesions was observed.

Discussion
Savolitinib is a novel reversible and competitive c-Met kinase inhibitor that has shown antitumor activities that are highly related to c-Met in both in vitro and in vivo studies. Based on preliminary safety and pharmacokinetic (PK) data obtained from the phase I clinical trial in Australia, a starting dose of 600 mg QD was deemed to be reasonable. In phase Ib, we assessed the safety and efficacy of this drug in patients with advanced gastric cancers or NSCLCs harboring aberrant c-Met.

Similar PK characteristics were observed across comparable doses and regimens, with an approximate doubling of the AUC following BID dosing compared to QD dosing. Furthermore, no apparent differences were observed in the PK profiles of savolitinib throughout all dosing regimens between Chinese patients enrolled in this study and Caucasian patients enrolled in the Australian trial.

All patients received at least one dose of savolitinib and were included in the safety analyses (n = 85). Treatment-related AEs (TRAEs) were predominantly grades 1-2, the most common grade ≥3 TRAEs were abnormal liver function (n = 7), fatigue (n = 2), diarrhea (n = 2), and reduced appetite (n = 2). We found that savolitinib was well tolerated up to 600 mg BID and no MTD was identified. The safety results were consistent with those of a previous first-in-human study conducted in Australia and those reported for other MET-specific inhibitors.

In the phase Ia study (n = 21), in which c-Met gene or protein expression status was not tested, no patients experienced a partial or complete response (PR or CR). In the phase Ib dose expansion (n = 64), we enrolled only patients with gastric cancer or non–small cell lung cancer (NSCLC) harboring MET aberration. The objective response rate (ORR) was 9.4% (6/64) in all patients, and the disease control rate was 39.1% (25/64). Notably, all PRs occurred in patients with gastric cancer with MET amplification rather than f MET over-expression. In NSCLC bearing MET exon 14 skipping mutations, apparent tumor shrinkage (55% and 27%) in target lesions was observed in 2 of 4 patients, although no responses met PR criteria (Fig. 1). The efficacy observed in this cohort should be interpreted with caution because of the limited number of patients.

We further analyzed the relationship between efficacy and the c-Met gene copy number (GCN) in gastric cancer. Interestingly, all patients who achieved PR had a high MET GCN; the median (range) MET GCN was 13.2 (9.7-18.4) and 14.7 (4.1-26.7) among responders and non-responders, respectively. In addition, in the phase Ib trial, we found 2 patients with gastric cancer with high met GCNs achieved a PR in target lesions, but new lesions appeared simultaneously, indicating gastric cancer is quite heterogeneous and the MET status should be interpreted in the context of a tumor’s genetic background to identify the true driver gene.

Figure 1. Waterfall plot of best tumor response and MET biomarker analysis; 46 patients shown in the figure were tumor-evaluable; the remaining 18 had either no baseline or no post-treatment tumor measurement data. Abbreviations: FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; G/GEJ, gastric/gastroesophageal cancer; NSCLC, non–small cell lung cancer.
**Trial Information**

| Disease                      | Advanced cancer/solid tumor only |
|------------------------------|----------------------------------|
| Stage of disease/treatment   | Metastatic/advanced              |
| Prior therapy                | More than 2 prior regimens       |
| Type of study                | Phase I, dose escalation + dose expansion |
| Primary endpoints            | Safety, tolerability, maximum tolerated dose, recommended phase II dose |
| Secondary endpoint          | Pharmacodynamics                 |
| Additional details of endpoints or study design | The study consisted of 2 parts: dose escalation (phase Ia) and dose expansion (phase Ib). The primary objectives were to evaluate the safety, tolerability, maximum tolerated dose (MTD), and RP2D of savolitinib. The secondary objective was to describe the PK and assess the clinical efficacy of savolitinib. Exploratory objectives included biomarker analysis. Safety and tolerability were evaluated through the incidence and nature of dose-limiting toxicities, adverse events (AEs), changes in vital signs, physical examination results, laboratory examination results, ECOG scores, and electroencephalography. TRAEs were graded using the National Cancer Institute’s Common Terminology Criteria for Adverse Events v4.3.1. Computed tomography was performed at baseline, on D1 of cycle 3 and D1 of every 2 subsequent cycles. The radiologic tumor response was assessed per RECIST version 1.1. |

**Investigator’s analysis** Active and should be pursued further

**Drug Information: Dose Escalation**

|Generic/working name| Savolitinib |
|Company name        | Hutchison China MediTech Limited |
|Drug type           | Small molecule |
|Drug class          | MET—cMET |
|Dose                | 600 mg QD, 800 mg QD, 400 mg BID, 500 mg BID, 600 mg BID per |
|Route               | Oral (p.o.) |
|Schedule of administration| During the dose escalation phase, participants were sequentially enrolled in a classic “3+3” design to receive one of the 5 savolitinib regimens (600 mg QD, 800 mg QD, 400 mg BID, 500 mg BID, and 600 mg BID) on a 21-day cycle. Patients with QD administration received a single-dose of savolitinib, followed by a 7-day washout period, and then completed 21-day continuous savolitinib administration at the same dose level. Patients administered BID only received 21-day treatment cycles of savolitinib. |

**Dose Escalation Table**

| Dose level | Dose of drug: savolitinib | Number enrolled | Number evaluable for toxicity |
|------------|---------------------------|-----------------|------------------------------|
| 1          | 600 mg QD                 | 4               | 4                            |
| 2          | 800 mg QD                 | 3               | 3                            |
| 3          | 400 mg BID                | 4               | 4                            |
| 4          | 500 mg BID                | 4               | 4                            |
| 5          | 600 mg BID                | 6               | 6                            |
| Dose expansion | 500 mg BID               | 46              | 46                           |
|            | 600 mg QD                 | 18              | 18                           |

**Drug Information: Dose Expansion**

|Generic/working name| Savolitinib |
|Company name        | Hutchison China MediTech Limited |
|Drug type           | Small molecule |
|Drug class          | MET—cMET |
|Dose                | 500 mg BID, 600 mg QD per |
|Route               | Oral (p.o.) |
|Schedule of administration| Participants in cohorts A and B received the RP2D (500 mg BID) identified in the dose escalation phase. Based on previously reported data, a dose of 600 mg QD also inhibited the c-MET target and exhibited antitumor efficacy in early clinical trials. Therefore, participants in cohorts C and D received a dose of 600 mg QD (weight >50 kg) or 400 mg QD (weight ≤ 50 kg) to further evaluate the safety and efficacy of savolitinib. In the present study process, no patient received a dose of 400 mg QD. |
### Patient Characteristics: Dose Escalation

| Characteristic                                      | Value                                                                 |
|-----------------------------------------------------|-----------------------------------------------------------------------|
| Number of patients, male                            | 12                                                                    |
| Number of patients, female                         | 9                                                                    |
| Stage                                               | I: $n = 1$  
II: $n = 1$  
III: $n = 7$  
IV: $n = 13$  |
| Age                                                 | Median (range): 57 (32-71) years                                     |
| Performance Status: ECOG                            | 0—3  
1—18  
2—0  
3—0  
Unknown—0                                           |
| Cancer types or histologic subtypes                 | Gastric/gastroesophageal junction cancer, 5  
Colon cancer, 5  
Rectum cancer, 4  
Kidney cancer, 6  
Others, 1                                              |

### Patient Characteristics: Dose Expansion

| Characteristic                                      | Value                                                                 |
|-----------------------------------------------------|-----------------------------------------------------------------------|
| Number of patients, male                            | 43                                                                    |
| Number of patients, female                         | 21                                                                    |
| Stage                                               | I: $n = 1$  
II: $n = 1$  
III: $n = 10$  
IV: $n = 52$  |
| Age                                                 | Median (range): 59 (26-81) years                                     |
| Performance Status: ECOG                            | 0—5  
1—59  
2—0  
3—0  
Unknown—0                                           |
| Cancer types or histological subtypes               | Lung cancer, 26  
Gastric/gastrointestinal cancer, 38                                   |

### Primary Assessment Method: Dose Escalation

| Title                                      | Toxicity                                                                 |
|--------------------------------------------|--------------------------------------------------------------------------|
| Number of patients screened                | 21                                                                       |
| Number of patients enrolled                | 21                                                                       |
| Number of patients evaluable for toxicity  | 21                                                                       |
| Number of patients evaluated for efficacy  | 18                                                                       |
| Evaluation method                          | National Cancer Institute's Common Terminology Criteria for Adverse Events v4.3.1 |

### Primary Assessment Method: Dose Expansion

| Title                                      | Efficacy                                                                 |
|--------------------------------------------|--------------------------------------------------------------------------|
| Number of patients screened                | 855                                                                      |
| Number of patients enrolled                | 64                                                                       |
| Number of patients evaluable for toxicity  | 64                                                                       |
| Number of patients evaluated for efficacy  | 45                                                                       |
| Evaluation method                          | RECIST 1.1                                                               |
| Response assessment CR                      | $n = 1$ (1.6%)                                                           |
| Response assessment PR                      | $n = 5$ (7.6%)                                                           |
Response assessment SD
\( n = 19 \) (29.7%)

Response assessment PD
\( n = 20 \) (31.3%)

Response assessment OTHER
\( n = 19 \) (29.7%)

(Median) duration assessments PFS
2.37 months, CI: 1.41-2.89

### Adverse Events: Dose Escalation, All Dose Levels, All Cycles

| Name              | *NC/NA | 1   | 2   | 3   | 4   | 5   | All grades |
|-------------------|--------|-----|-----|-----|-----|-----|------------|
| Nausea            | 71%    | 22% | 6%  | 1%  | 0%  | 0%  | 29%        |
| Vomiting          | 73%    | 18% | 7%  | 2%  | 0%  | 0%  | 27%        |
| Anorexia          | 81%    | 14% | 2%  | 2%  | 0%  | 0%  | 19%        |
| Edema limbs       | 84%    | 15% | 1%  | 0%  | 0%  | 0%  | 16%        |
| Fatigue           | 92%    | 5%  | 1%  | 2%  | 0%  | 0%  | 8%         |
| Diarrhea          | 98%    | 0%  | 0%  | 2%  | 0%  | 0%  | 2%         |
| Neutrophil count decreased | 92% | 5% | 2% | 1% | 0% | 0% | 8% |
| Platelet count decreased | 94% | 4% | 0% | 2% | 0% | 0% | 6% |
| Anemia            | 96%    | 2%  | 0%  | 1%  | 0%  | 0%  | 4%         |

Key treatment related adverse events, all cycles. See also Table 1.

All patients received at least one dose of savolitinib and were included in the safety analyses (\( n = 85 \); Table 2). Treatment-related AEs occurred in 71 (83.5%) patients.

The most common TRAEs were nausea (29.4%), vomiting (27.1%), reduced appetite (18.8%), peripheral edema (16.5%), and abnormal liver function (16.5%). Treatment-related AEs were predominantly grades 1-2, the most common grade ≥3 TRAEs were abnormal liver function (\( n = 7 \)), fatigue (\( n = 2 \)), diarrhea (\( n = 2 \)), and reduced appetite (\( n = 2 \)). Overall, TRAE incidences were higher in the QD group than in the BID group (88% vs. 75%); however, patients in the BID group experienced more nausea and vomiting, and grade ≥3 TRAEs were more frequent in the BID group. Sixteen patients (18.8%) experienced serious TRAEs. Twenty patients (23.5%) discontinued treatment due to TRAEs, and dose adjustment or interruption due to TRAEs was reported in 15 patients (17.6%).

Five patients (5.9%) had fatal AEs; most (\( n = 4 \)) were related to underlying disease. One patient from cohort A1 reported perforation and finally died 7 days after diagnosis. Only this death was deemed related to treatment by investigators.

*NC/NA, no change from baseline/no adverse event.

### Serious Adverse Events

| Name               | Grade | Attribution |
|--------------------|-------|-------------|
| Inguinal hernia     | 3     | Unrelated   |

One (1) serious adverse event (SAE), Grade 3 inguinal hernia, was reported in one patient treated with savolitinib 500 mg BID.

### Adverse Events: Dose Expansion, Cycle 1

| Name                  | *NC/NA | 1   | 2   | 3   | 4   | 5   | All grades |
|-----------------------|--------|-----|-----|-----|-----|-----|------------|
| Nausea                | 0%     | 68% | 26% | 5%  | 0%  | 0%  | 100%       |
| Vomiting              | 0%     | 53% | 35% | 12% | 0%  | 0%  | 100%       |
| Diarrhea              | 0%     | 75% | 0%  | 25% | 0%  | 0%  | 100%       |
| Fatigue               | 0%     | 67% | 17% | 17% | 0%  | 0%  | 100%       |
| White blood cell decreased | 0% | 67% | 33% | 0%  | 0%  | 0%  | 100%       |
| Anemia                | 0%     | 100%| 0%  | 0%  | 0%  | 0%  | 100%       |
| Platelet count decreased | 0% | 100%| 0%  | 0%  | 0%  | 0%  | 100%       |
| Edema limbs           | 0%     | 67% | 33% | 0%  | 0%  | 0%  | 100%       |
| Alanine aminotransferase increased | 0% | 50% | 25% | 25% | 0%  | 0%  | 100%       |

*NC/NA, no change from baseline/no adverse event.

### Serious Adverse Events

| Name               | Grade | Attribution |
|--------------------|-------|-------------|
| Hepatic function abnormal | 3     | Probable    |
| Interstitial lung disease | 3     | Probable    |
| Diarrhea           | 3     | Probable    |
| Edema              | 3     | Probable    |
| Cardiotoxicity     | 3     | Probable    |
| Decreased appetite | 3     | Probable    |
Dysregulation of the HGF/MET (c-Met, also called tyrosine protein kinase Met or hepatocyte growth factor receptor, is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity) signaling pathway has been implicated in the tumorigenesis of various human cancers.1-3 Savolitinib is a novel reversible and competitive c-Met kinase inhibitor that has shown antitumor activities and is highly related to c-Met alterations in both in vitro and in vivo studies.4 A first-in-human phase I clinical study of savolitinib was conducted in patients with advanced solid tumors in Australia using doses of 100-1000 mg QD and 300-500 mg BID showed preliminary efficacy in patients with papillary renal cell carcinoma with MET gene copy number (GCN) changes.5 However, biomarkers of savolitinib need further investigation.

Thus, we conducted a phase Ia/Ib trial of savolitinib in Chinese patients with solid tumors. Savolitinib demonstrated a manageable safety profile and promising antitumor activity in gastric cancer with c-met amplification and NSCLC with MET exon 14 skipping mutation.

We found that savolitinib was well tolerated up to 600 mg BID and no MTD was identified. The safety results were consistent with those of a previous first-in-human study conducted in Australia and those reported by other MET-specific inhibitors.5-7 Although the vast majority of patients (83.5%) reported TRAEs during treatment, most were grades 1-2 (Table 1). Notably, in the dose escalation phase, we found that patients in the BID cohorts experienced more nausea and vomiting than the QD cohorts. Fortunately, these AEs are easily manageable with the application of antiemetics in clinical practice, and will not lead to more discontinuation or interruption events (Table 1).

The exposure to savolitinib reached steady state shortly after oral administration in the 500 mg BID group, and there was no significant drug accumulation. As the dose increased to 600 mg BID, the plasma exposure of savolitinib and its metabolite remained at the same level as that of 500 mg BID, indicating that the 600 mg BID dose may not enhance the inhibition of c-Met kinase phosphorylation relative to 500 mg BID (Table 3 and Fig. 3). Further, antitumor activity was observed at a dose of 600 mg QD in the phase I Australia study.5 Therefore, based on the safety, tolerability, preliminary efficacy, and PK profile, 500 mg BID or 600 mg QD was determined as the recommended dose for savolitinib monotherapy in phase Ib/II studies.

Patients were not selected based on MET status in the phase Ia study (Fig. 2), and no objective response was observed in this part of the study, suggesting that savolitinib warrants further investigation in cancer patients with c-MET dysregulation. The most common mechanism of MET pathway abnormal activation in gastric cancer is via protein overexpression or MET gene amplification; therefore, we analyzed the relationship between efficacy and the 2 types of c-met aberrations in patients with gastric cancer in the phase Ib study. Notably, only patients with gastric cancer with C-MET amplification had a high response rate to savolitinib. We further analyzed the relationship between efficacy and the c-Met GCN in gastric cancer. Interestingly, all patients who experienced PR had tumors with a high MET GCN, with a median (range) MET
GCN of 13.2 (9.7-18.4). The relationship between efficacy and MET CNG is shown in Fig. 4. This is consistent with the findings of a previous study. In the reported VIKTORY umbrella trial, the ORR of savolitinib monotherapy in MET-amplified gastric cancer that had progressed on standard treatment reached 50% (10/20). Subsequent biomarker analysis revealed that among the 10 patients who achieved PR, 7 had a MET GCN >10 and 3 had a GCN of 5-10. Therefore, when considering MET-targeted treatment options, MET amplification may be more predictive of response in gastric cancer than MET protein over-expression because the latter typically occurs in the background of other strong genetic events rather than as an isolated driver event.15,16

Aside from savolitinib, another highly selective small-molecule inhibitor of the MET receptor signaling pathway, AMG 337, has been investigated in gastric/GEJ adenocarcinoma.17 Phase II results of AMG 337 showed antitumor activity in MET-amplified gastric/GEJ/esophageal adenocarcinoma with an ORR of 18%, and the median MET GCN of responders and non-responders was 7.7 (2.4-12) and 7.1 (2.0-20.4), respectively.15 Subsequent biomarker analysis in both studies indicated that not all patients with high MET GCNs responded to MET inhibitors, while all patients with responding disease had a high GCN. This implies that the c-MET signaling pathway in gastric cancer is more complicated. It has been shown that the complexity of the MET signaling pathway, as well as the diverse resistance mechanisms (cross-talk, new mutations, upregulated gene amplification), all limited the clinical efficacy of MET inhibition.13 However, gastric cancer is quite heterogeneous; in the phase Ib trial, 2 patients with gastric cancer with high MET GCNs achieved a PR in target lesions, but new lesions appeared simultaneously. Taken together, our findings indicate that the MET status should be interpreted in the context of a tumor’s genetic background to identify the driver gene. Several novel inhibitors have recently been approved in the treatment of NSCLC, including MET-specific inhibitors (capmatinib and tepotinib) and multiple-targeted inhibitors (crizotinib and cabozantinib).14,15 The MET exon 14 skipping mutation has been validated as a biomarker in previous studies.14,15 The MET exon 14 skipping mutation has been validated as a biomarker in previous studies.14,15 In the present study, while no PR was observed in cohort D, we observed apparent tumor shrinkage in 2 of 4 patients, supporting further investigation of savolitinib in NSCLC harboring MET exon 14 skipping mutation.

In summary, in this phase Ia/Ib clinical study, savolitinib demonstrated good tolerability and exhibited promising signs of antitumor activity in gastric cancers with MET amplification and NSCLC with exon 14 skipping mutation. Future studies are necessary to confirm the clinical efficacy and determine which signaling pathway contributes to resistance.

Acknowledgments

We thank the patients who participated in this study, as well as their families and caregivers, and the staff and investigators at all the study sites. We also thank AJE (www.aje.cn) for the English language review. The research presented in this article was funded by Hutchison MediPharma Ltd and AstraZeneca.

Conflict of Interest

The authors indicated no financial relationships.

Data Availability

The data underlying this article are available in the article and in its online supplementary material.

References

1. El Darsa H, El Sayed R, Abdel-Rahman O. MET inhibitors for the treatment of gastric cancer: what’s their potential? J Exp Pharmacol. 2020;12:349-361.
2. Moosavi F, Giovannetti E, Saso L, Firuzi O. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci. 2019;56(8):533-566.
3. Lennerz JK, Kwak EL, Ackerman A, et al MET amplification identifies a small and aggressive subgroup of esophagealgastric adeno - carcinomawith evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29(36):4803-4810.
4. Gavine PR, Ren Y, Han L, et al Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived xenograft models. Mol Oncol. 2015;9(1):323-333.
5. Gan HK, Millward MJ, Hua Y, et al First-in-human phase I study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, pharmacokinetics and anti-tumor activity. Clin Cancer Res. 2019;25(16):4924-4932.
6. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89-103.
7. Kawakami H, Okamoto I, Okamoto W, Tanizaki J, Nakagawa K, Nishio K. Targeting MET amplification as a new oncogenic driver. Cancers (Basel). 2014;6(3):1540-1552.
8. Lee J, Kim ST, Kim K, et al Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: the VIKTORY Umbrella Trial. Cancer Discov. 2019;9(10):1388-1405.
9. Chatterjee A, Rodger EJ, Eccles MR. Epigenetic drivers of tumourigenesis and cancer metastasis. Semin Cancer Biol. 2018;51:149-159.
10. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7(6):504-516.
11. Hong DS, LoRusso P, Hamid O, et al First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors. J Clin Oncol. 2014;32:2508-2508.
12. Van Cutsem E, Karaszewska B, Kang Y-K, et al A multicenter phase II study of AMG 337 in patients with <em>em>MET</em>-amplified gastric/gastroesophageal junction/esophageal adenocarcinoma and other <em>em>MET</em>-amplified solid tumors. Clin Cancer Res. 2019;25:2414.
13. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(1 Suppl):S7-S19.
14. Puccini A, Marin-Ramos NI, Bergamo F, et al Safety and tolerability of c-MET inhibitors in cancer. Drug Saf. 2019;42(2):211-233.
15. Wang Q, Yang S, Wang K, Sun SY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;12(1):63.
16. Salgia R, Sattler M, Scheele J, Stroh C, Felip E. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020;87:102022.
Figure 2. Patient disposition (dose escalation and expansion). Phase Ia study followed a 3+3 design and a total of 21 patients being treated. A total of 64 patients were enrolled into 5 cohorts according to MET status in phase Ib study.

Figure 3. Plasma concentration-time of savolitinib after single and repeated dose of savolitinib at 600 mg QD, 800 mg QD (A) and 400 mg BID, 500 mg BID, and 600 mg BID (B).
Figure 4. The relationship between efficacy and MET CNG in gastric cancer patients. Responders: with tumor shrinkage in target lesions, \( n = 10 \); non-responders: without tumor shrinkage in target lesions, \( n = 7 \).

Table 1. Treatment-related safety summary.

| Adverse events, \( n \) (%) | Dose escalation, mg | Dose expansion, mg | Overall | \( N = 85 \) |
|---------------------------|---------------------|-------------------|---------|-------------|
|                           | 600 QD \( (n = 4) \) | 800 QD \( (n = 3) \) | 400 bid \( (n = 4) \) | 500 bid \( (n = 4) \) | 600 bid \( (n = 6) \) | 500 bid \( (n = 46) \) | 600 QD \( (n = 18) \) |
| AE incidence              | 3 (75)              | 3 (100)           | 4 (100) | 4 (100)     | 5 (83.3)              | 44 (95.7) | 18 (100)     | 81 (95.3) |
| TRAE incidence            | 3 (75)              | 3 (100)           | 4 (100) | 3 (75)      | 5 (83.3)              | 37 (80.4) | 16 (88.9)    | 71 (83.5) |
| TRAE leading to treatment interruption | 1 (25)             | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                  | 9 (19.6)  | 5 (27.8)     | 15 (17.6) |
| TRAE leading to treatment discontinuation | 1 (25)             | 0 (0)             | 0 (0)   | 0 (0)       | 1 (16.7)              | 14 (30.4) | 4 (22.2)     | 20 (23.5) |
| Treatment-related SAE    | 0 (0)               | 0 (0)             | 0 (0)   | 1 (25)      | 0 (0)                  | 11 (23.9) | 4 (22.2)     | 16 (18.8) |
| TRAE leading to death    | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                  | 1 (2.2)   | 0 (0)        | 1 (1.2)   |
| DLT: Fatigue             | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 1 (16.7)              | 0 (0)     | 0 (0)        | 1 (1.2)   |
| TRAE of any grade in \( \geq 10\% \) of patients | | | | | | | | |
| Nausea                   | 0 (0)               | 0 (0)             | 2 (50)  | 2 (50)      | 4 (66.7)              | 16 (34.8) | 1 (5.6)      | 25 (29.4) |
| Vomiting                 | 0 (0)               | 1 (33.3)          | 0 (0)   | 3 (75)      | 4 (66.7)              | 12 (26.1) | 3 (16.7)     | 23 (27.1) |
| Decreased Appetite       | 0 (0)               | 1 (33.3)          | 1 (25)  | 2 (50)      | 2 (33.3)              | 9 (19.6)  | 1 (5.6)      | 16 (18.8) |
| Peripheral edema         | 1 (25)              | 1 (33.3)          | 2 (50)  | 0 (0)       | 0 (0)                 | 5 (10.9)  | 5 (27.8)     | 18 (21.2) |
| Abnormal liver function  | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 12 (26.1) | 2 (11.1)     | 14 (16.5) |
| TRAEs grade 3 or higher  | | | | | | | | |
| Fatigue                  | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 1 (16.7)              | 1 (2.2)   | 0 (0)        | 2 (2.4)   |
| Hemoglobin decreased     | 1 (25)              | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 0 (0)     | 0 (0)        | 2 (2.4)   |
| Neutrophil count decreased| 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 1 (2.2)   | 0 (0)        | 1 (1.2)   |
| Platelet count decreased  | 1 (25)              | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 0 (0)     | 1 (5.6)      | 2 (2.4)   |
| Abnormal liver function  | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 7 (15.2)  | 0 (0)        | 7 (8.2)   |
| Diarrhea                 | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 2 (4.3)   | 0 (0)        | 2 (2.4)   |
| Abdominal pain           | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 1 (2.2)   | 0 (0)        | 1 (1.2)   |
| Perforation              | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 1 (2.2)   | 0 (0)        | 1 (1.2)   |
| Nausea                   | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 1 (2.2)   | 0 (0)        | 1 (1.2)   |
| Vomiting                 | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 1 (2.2)   | 0 (0)        | 1 (1.2)   |
| Decreased appetite       | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 2 (4.3)   | 0 (0)        | 2 (2.4)   |
| Interstitial lung disease| 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 1 (2.2)   | 0 (0)        | 1 (1.2)   |
| ALB decreased            | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 1 (2.2)   | 0 (0)        | 1 (1.2)   |
| Heart toxicity           | 0 (0)               | 0 (0)             | 0 (0)   | 0 (0)       | 0 (0)                 | 0 (0)     | 1 (5.6)      | 1 (1.2)   |

Abbreviations: AE, adverse event; ALB, albumen; DLT, dose-limiting toxicity; SAE, serious adverse event; TRAE, treatment-related adverse events.
| Efficacy | Dose escalation (N = 21) | Dose expansion, mg | Total (N = 64) |
|----------|-------------------------|--------------------|---------------|
|          | 500 bid (n = 7)         | 500 bid (n = 17)   | 500 bid (n = 22) | 600 QD (n = 14) | 600 QD (n = 4) |
|          | Cohort A1               | Cohort A2          | Cohort B       | Cohort C       | Cohort D       |
| CR, n (%)| 0 (0)                   | 0 (0)              | 0 (0)          | 1 (7.1)        | 0 (0)          | 1 (1.6)        |
| PR, n (%)| 0 (0)                   | 1 (13.3)           | 0 (0)          | 0 (0)          | 4 (28.6)*      | 0 (0)          | 5 (7.8)        |
| SD, n (%)| 8 (38.1)                | 1 (13.3)           | 3 (17.6)       | 9 (40.9)       | 4 (28.6)       | 2 (50)         | 19 (29.7)      |
| PD, n (%)| 10 (47.6)               | 2 (28.6)           | 9 (53)         | 5 (22.7)       | 3 (21.4)       | 1 (25)         | 20 (31.3)      |
| NE, n (%)| 3 (14.3)                | 3 (42.9)           | 5 (29.4)       | 8 (36.4)       | 2 (14.3)       | 1 (25)         | 19 (29.7)      |
| ORR, n (%)| 0 (0)                   | 1 (13.3)           | 0 (0)          | 0 (0)          | 5 (35.7)       | 0 (0)          | 6 (9.4)        |
| DCR, n (%)| 8 (38.1)                | 2 (28.6)           | 3 (17.6)       | 9 (40.9)       | 9 (64.3)       | 2 (50)         | 25 (39.1)      |
| mPFS, 95% CI| NK                     | 1.38 (0.33-46.95)  | 1.40 (0.95-1.45) | 2.73 (1.41-4.07) | 2.73 (1.41-4.07) | 2.37 (1.84-6.90) | 2.37 (1.41-2.89) |

Abbreviations: CR, complete response; DCR, disease control rate; mPFS, median progression-free survival; NE, not evaluable; NK, not known; PD, progressive disease; PR, partial response; SD, stable disease.
Table 3. Pharmacokinetic parameters of savolitinib on circle 1 day 1 and circle 1 day 21 after repeated QC (600 mg, 800 mg) and bid (400 mg, 500 mg, 600 mg)

| PK parameters | Day 1 | Day 21 |
|---------------|-------|--------|
|               | 600 mg QD | 800 mg QD | 400 mg bid | 500 mg bid | 600 mg bid | 600 mg QD | 800 mg QD | 400 mg bid | 500 mg bid | 600 mg bid |
|               | (n = 22) | (n = 3) | (n = 4) | (n = 47) | (n = 6) | (n = 20) | (n = 3) | (n = 3) | (n = 29) | (n = 4) |
| aAUC_{0~t} (ng·h mL⁻¹) | 17099a (7062) | 32167a (10966) | 13015a (4011) | 15067a (6612) | 16490a (5917) | 20005a (6569) | 37133a (10923) | 15067a (6612) | 16490a (5917) | 20005a (6569) |
| aAUC_{0~inf} (ng·h mL⁻¹) | 17503a (7282) | 32733a (11570) | 13720a (4652) | 18864a (9186) | 17258a (7198) | 20415a (6791) | 37600a (11130) | 23400a (3960) | 34290a (1040) | 47950a (44624) |
| aC_{max} (ng mL⁻¹) | 24.32 (1093) | 41.33 (944) | 26.80 (982) | 28.30 (1218) | 31.13 (714) | 29.62 (1171) | 55.03 (775) | 29.90 (1317) | 34.29 (1040) | 32.8 (1398) |
| bT_{max} (h) | 2b (0.5-6) | 4b (2-2) | 4b (0.5-8) | 2b (2.6) | 2b (0.5-6) | 4b (2-4) | 4b (1-6) | 4b (0.5-5.52) | 4b (4-8) |
| at1/2 (h) | 4.1a (0.8) | 3.6 (0.8) | 3.6 (1.1) | 4.1 (2.6) | 3.0 (0.4) | 3.88 (0.7) | 3.6 (0.1) | 3.5 (0.9) | 4.8 (2.4) | 8.6 (10) |

Abbreviations: AUC, area under the curve; PK, pharmacokinetics.